HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 2423051707v1 242/3/882    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mujoomdar, A. Articles by Raftopoulos, H. Search for Related Content PubMed PubMed Citation Articles by Mujoomdar, A. Articles by Raftopoulos, H.

Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases¹

¹ From the Departments of Radiology (A.M., J.H.M.A., R.M., G.D.N.P., M.C.S.) and Medicine (C.A.P., H.R.), Columbia University Medical Center, New York, NY. From the 2000 RSNA Annual Meeting. Received October 19, 2005; revision requested December 9; revision received February 28, 2006; accepted March 28; final version accepted May 31. Supported by the Saskatchewan Lung Association, the CRH Foundation, and the Department of Radiology, Columbia University. Address correspondence to A.M., Department of Radiology, Montreal General Hospital, McGill University, 1650 Cedar Ave, Room C5 118, Montreal, QC, Canada H3G 1A4 (e-mail: amm921{at}hotmail.com).

Purpose: To retrospectively assess possible clinical predictors of metastatic disease to the brain in patients with non–small cell lung carcinoma (NSCLC).

Materials and Methods: Institutional review board approval was obtained, informed consent was waived, and data and other information were obtained prior to implementation of HIPAA. A review was performed of 264 patients (mean age, 65 years; 158 men and 106 women) with NSCLC who had undergone imaging studies of the chest and head. Hierarchical logistic regression was used to determine the predicted probability of metastatic disease to the brain as a function of patient age and sex and of size, cell type, peripheral versus central location, and lymph node stage of the primary NSCLC.

Results: Ninety-five (36%) patients had evidence of metastatic disease to the brain. Mean diameter of the primary tumors was 4.0 cm ± 2.2 (standard deviation). Cell types included adenocarcinoma (136 [52%] patients), undifferentiated (68 [26%] patients), and squamous (47 [18%] patients), for which metastatic disease to the brain occurred in 43%, 41%, and 13% (P = .003) of patients, respectively. The predicted probability of metastatic disease to the brain correlated positively with size of the primary tumor (P < .001), cell type (adenocarcinoma and undifferentiated vs squamous, P = .001), and lymph node stage (P < .017) but did not correlate with age, sex, or primary tumor location. For primary adenocarcinoma without lymph node spread, the predicted probabilities of metastatic disease to the brain from 2- and 6-cm primary tumors were .14 (95% confidence interval: .06, .27) and .72 (95% confidence interval: .48, .88), respectively (P < .02).

Conclusion: The probability of metastatic disease to the brain from primary NSCLC is correlated with size of the primary tumor, cell type, and intrathoracic lymph node stage.

© RSNA, 2007